 |
1 Disease |  |
6 Trials |
|
6 Trials |  |
1075 News |  |
| «12345678910111213...1314» |
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Effectivity of Andexanet Alfa for the Reversal of Factor Xa Inhibitors under Hemodilution (Exhibition) - May 13, 2022 - Abstract #ISTH2022ISTH_1879;
Andexanet spiking of non-anticoagulated blood samples prolonged RVV test’s clotting time (CT) (Figure 2). Hemodilution prolonged clotting parameters further and reduced mean clot firmness (MCF).
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Direct comparison of Andexanet alfa and prothrombin complex concentrates in the reversal of direct factor Xa inhibitors – An in vitro study (Exhibition) - May 13, 2022 - Abstract #ISTH2022ISTH_1855;
Clotting time and clot resistance to fibrinolytic breakdown was also corrected over the full range of applied FXaI (0-800 ng/ml). 4F-PCC in increasing dose (0.625, 1.25 and 2 IU/ml; ~25, 50 and 80 IU/kg) only partially restored thrombin generation lag time and clotting time.
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Assessing the reversal efficacy of prothrombin complex concentrate (PCC) and andexanet alfa in rivaroxaban-anticoagulated blood: Ex vivo study (Exhibition) - May 13, 2022 - Abstract #ISTH2022ISTH_1744;
Independent of rivaroxaban concentration, andexanet normalized or overcompensated all TG parameters. PCC showed no significant improvement on TG.
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Andexanet alfa is associated with a significant reduction in in-hospital mortality compared to 4F-PCC in a real-world analysis (ExCel Center, ICC Capital Suite Room 8&9) - May 13, 2022 - Abstract #ISTH2022ISTH_1725;
Unadjusted baseline characteristics, including time since last anticoagulant dose, were similar between groups (Table 1). Gastrointestinal (GI) was the most common type of bleed, and most bleeds were spontaneous (Table 1).
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa (Exhibition) - May 13, 2022 - Abstract #ISTH2022ISTH_1131;
The ANOVA test yielded a significant result when comparing the means of UFH treated at various andexanet alfa concentrations. The Tukey Post-Hoc test revealed significant differences between the UFH and UFH treated with andexanet alfa at all concentrations tested except at 6.25 μg/ml.
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
VALIDATION OF A TREATMENT DECISION ALGORITHM FOR THE USE OF ANDEXANET ALFA IN ACUTE LIFE-THREATENING BLEEDING FROM DIRCT FACTOR Xa INHIBITORS (ExCel Center, ICC Capital Suite Room 14-16) - May 13, 2022 - Abstract #ISTH2022ISTH_889;
Of the 100 patients, 7% had aXa activities 18 hours” (as applied in AA trials and used in clinical routine) would have excluded 12% from AA therapy, of whom 4 (33%) had aXa activities > 75 ng/ml. Table 1 indicates that, without an algorithm, the risk of over-treatment increases with increasing treatment indication thresholds.
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Real-world Use of Andexanet Alfa for Anti-Xa Inhibitor Reversal: A Case Series (Exhibition) - May 13, 2022 - Abstract #ISTH2022ISTH_734;
Median patient age was 68 (interquartile range: 58-75), 60% were female, 80% were white, and 66% were receiving apixaban. The most common indication for andexanet was intracranial bleeding (73.3%).
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Effects of andexanet alfa on different thrombin generation and anti-Xa-methods in vitro. (ExCel Center, ICC Capital Suite Room 10&11) - May 13, 2022 - Abstract #ISTH2022ISTH_361;
An overshoot of baseline TG levels was noticed after adding andexanet, which was reversed by a TFPI-antibody. Small differences were found between the CAT-1 and ST Genesia measurement.
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Journal: Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa. (Pubmed Central) - May 12, 2022
Small differences were found between the CAT-1 and ST Genesia measurement. Andexanet partially neutralized UFH and LMWH with variability between assays, necessitating investigation into assay-dependent differences.
- || AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Clinical, Journal: Andexanet alfa for reversal of rivaroxaban in a child with intracranial hemorrhage. (Pubmed Central) - Apr 27, 2022
Andexanet partially neutralized UFH and LMWH with variability between assays, necessitating investigation into assay-dependent differences. No abstract available
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Case series of the first use of Andexanet Alfa at Salisbury NHS Foundation Trust () - Apr 25, 2022 - Abstract #BSH2022BSH_250;
Accordingly, SFTs are implementing quality assured DOAC specific Anti-Xa assays to appropriately assess DOAC levels in the setting of Andexanet Alfa use. SFT has now incorporated the NICE Guidance into its practice since May 2021 and now only uses Andexanet Alfa for reversing anticoagulation from apixaban or rivaroxaban in adults with life threatening or uncontrolled bleeding in the gastrointestinal tract.
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Retrospective data, Journal: Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis. (Pubmed Central) - Apr 21, 2022
This study found no significant differences in good or excellent ICH hemostasis within 24-h or new thrombotic events within 14-days in a cohort given AA or 4F-PCC for ICH while on apixaban or rivaroxaban. However, this single-center analysis is underpowered due to sample size constraints, therefore further high-quality research comparing AA safety and effectiveness versus 4F-PCC is needed.
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Retrospective data, Journal: Evaluation of andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages. (Pubmed Central) - Apr 21, 2022
No statistically significant differences were identified in primary or secondary outcomes between the two agents with the exception of total treatment cost. There is insufficient evidence based on this study to recommend AA over 4F-PCC for patients with intracranial hemorrhages associated with the use of apixaban or rivaroxaban.
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Journal: Difficulties Detecting Clinically Relevant Factor Xa Inhibitor Levels Prior to Reversal With Andexanet Alfa for Intracranial Hemorrhage. (Pubmed Central) - Apr 15, 2022
These cases highlight the challenges clinicians are facing when using andexanet alfa for emergent rivaroxaban or apixaban reversal when the timing of last dose is unknown, or patients fall outside of the recommended timeframe for use and clinically relevant drug levels are still suspected. Based on our experiences, we encourage other institutions to evaluate their abilities to rapidly and accurately detect the presence of clinically relevant rivaroxaban and apixaban levels when utilizing andexanet alfa.
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Journal: Impact of a pharmacist driven anticoagulation reversal program at a large academic medical center. (Pubmed Central) - Apr 7, 2022
To our knowledge, this is the first study to evaluate the impact of a pharmacist-driven ARP on clinical and economic outcomes. Implementation of a pharmacist-driven ARP was associated with favorable outcomes and cost savings.
- || AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Clinical, Journal: Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. (Pubmed Central) - Apr 7, 2022
Discharge to skilled nursing facilities and 30-day readmission were similar between groups. In this cohort, reversal with andexanet alfa and 4F-PCC differed in terms ofhemostatic efficacy and thrombotic events after ICH in patients anticoagulated with apixaban or rivaroxaban.
- || AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Clinical, Journal: Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series. (Pubmed Central) - Apr 7, 2022
In this cohort, reversal with andexanet alfa and 4F-PCC differed in terms ofhemostatic efficacy and thrombotic events after ICH in patients anticoagulated with apixaban or rivaroxaban. In our case series, obtaining anti-Xa DOAC levels prior to administration of andexanet alfa was achievable and facilitated use of reversal agents in patients with major bleeding or emergent procedural need.
- || AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Clinical, Journal: Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria. (Pubmed Central) - Apr 7, 2022
Five (10%) patients had thromboembolic events within seven days of PCC administration, and the 30-day mortality rate was 14% (7/50). Our study shows similar efficacy, thromboembolic events, and mortality associated with PCC compared to andexanet alfa using ANNEXA-4 criteria, suggesting that PCC may be a viable alternative.
- || AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Clinical, Journal: Modeling the Clinical Implications of Andexanet Alfa in Factor Xa Inhibitor-Associated Intracerebral Hemorrhage. (Pubmed Central) - Apr 7, 2022
Even optimistic simulated hemostatic effects suggest that the costs and potential benefits of andexanet alfa should be carefully considered. Placebo-controlled randomized trials are needed before its use can definitively be recommended.
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Journal: Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. (Pubmed Central) - Apr 5, 2022
Forty-four percent (n = 12) would choose andexanet alfa as first-line treatment for life-threatening bleeding while 52% (n = 14) would use PCC first with one individual choosing recombinant factor VII for DXI reversal. Clinical studies of andexanet alfa and PCC for the management of DXI-associated life-threatening bleeding require further investigation in the pediatric population.
- ||| Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Clinical guideline, Review, Journal: American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. (Pubmed Central) - Apr 5, 2022
In the elective periprocedural endoscopy setting, we could not recommend for or against temporary interruption of the P2Y receptor inhibitor for patients on a single P2Y inhibiting agent. We were also unable to make a recommendation regarding same-day resumption of the drug vs 1-7 days after the procedure among patients prescribed anticoagulants (warfarin or DOACs) or P2Y receptor inhibitor drugs because of insufficient evidence.
- ||| Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Clinical guideline, Journal: American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. (Pubmed Central) - Apr 2, 2022
In the elective periprocedural endoscopy setting, we could not recommend for or against temporary interruption of the P2Y12 receptor inhibitor for patients on a single P2Y12 inhibiting agent. We were also unable to make a recommendation regarding same-day resumption of the drug vs 1-7 days after the procedure among patients prescribed anticoagulants (warfarin or DOACs) or P2Y12 receptor inhibitor drugs because of insufficient evidence.
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Ondexxya approved in Japan for FXai reversal https://t.co/FSbeEHt518 (Twitter) - Mar 28, 2022
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Journal, HEOR: Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US. (Pubmed Central) - Mar 23, 2022
(1) Absence of head-to-head trials comparing therapies included in the economic model, (2) lack of comparative long-term data on treatment efficacy, and (3) bias resulting from the study designs of published literature. Given these results, the use of andexanet alfa for the reversal of anticoagulation in patients with factor Xa inhibitor-related ICH may improve quality of life and is likely to be cost-effective in a US context.
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
REVERSAL OF DIRECT FACTOR XA INHIBITORS WITH ANDEXANET ALFA PRIOR TO INVASIVE OR SURGICAL PROCEDURES ([VIRTUAL]) - Mar 23, 2022 - Abstract #SCCM2022SCCM_1894;
AA may be utilized for urgent or emergent reversal of apixaban and rivaroxaban peri-procedurally with promising hemostatic outcomes. Further prospective, comparative research is warranted.
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca, Feiba (human plasma derived anti-inhibitor coagulant complex) / Takeda
FEIBA AND ANDEXANET ALFA FOR THE REVERSAL OF APIXABAN AND RIVAROXABAN IN UNCONTROLLED HEMORRHAGE ([VIRTUAL]) - Mar 23, 2022 - Abstract #SCCM2022SCCM_1891;
The overall rates of effective hemostasis, mortality, thrombosis, and hemorrhagic complication were similar in the FEIBA and andexanet alfa groups after propensity matching. Due to our small population size, larger prospective studies are needed to evaluate the use of FEIBA versus andexanet alfa to determine effectiveness between agents.
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
COMPARISON OF 4F-PCC AND ANDEXANET ALFA FOR REVERSAL OF APIXABAN- AND RIVAROXABAN-ASSOCIATED ICH ([VIRTUAL]) - Mar 23, 2022 - Abstract #SCCM2022SCCM_1730;
Due to our small population size, larger prospective studies are needed to evaluate the use of FEIBA versus andexanet alfa to determine effectiveness between agents. In patients who experienced an ICH while taking apixaban or rivaroxaban, 4F-PCC and andexanet alfa were found to have similar rates of excellent or good hemostatic efficacy.
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
FOUR-FACTOR PCC VERSUS ANDEXANET ALFA FOR ORAL FACTOR XA INHIBITOR-ASSOCIATED MAJOR BLEEDS ([VIRTUAL]) - Mar 23, 2022 - Abstract #SCCM2022SCCM_1334;
This study showed no statistical difference in the rates of clinical hemostasis, in-hospital mortality, thromboembolism, or blood product consumption in the studied population. 4F-PCC and andexanet alfa have shown to be equally effective for treating factor Xa-associated major bleeding events with no difference in thromboembolism
- | tranexamic acid oral / Generic mfg.
Journal: Direct (new) oral anticoagulants (DOACs): Drawbacks, bleeding and reversal. (Pubmed Central) - Mar 16, 2022
Management recommendations for hemorrhage associated with DOAC use vary, depending on the class of the culprit agent (direct thrombin inhibitor vs. FXa inhibitor), the clinical status of the patient (mild/ moderate vs. severe/life-threatening), and capabilities of the institution. Specific reversal agents (i.e., idarucizumab and andexanet alfa) can be used if available, while prothrombin complex concentrates, fresh frozen plasma and/ or tranexamic acid can also be employed as nonspecific replacement agents in the management of DOAC-related bleeding diathesis.
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Journal: Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding. (Pubmed Central) - Mar 15, 2022
This indirect comparison was limited in that it could not account for several highly predictive variables including GCS score, hematoma volume, and expected survival. Further research is warranted to confirm the mortality differences between reversal/replacement agents for DOAC-related bleeding.
- ||| Kcentra (plasma-derived prothrombin complex concentrate) / CSL Behring, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Clinical: Absolutely - this was my experience during PGY2 as well (pharmacy recon'ed Kcentra doses at bedside housewide). Would be interesting if time differences between PCC and Andexxa had a meaningful clinical impact. That's something I have not seen (Twitter) - Mar 13, 2022
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Budget Impact of Andexanet ALFA for Gastrointestinal Bleeding Associated with Factor Xa Inhibitors from a US Hospital Perspective (In-person & Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1458;
Further research is warranted to confirm the mortality differences between reversal/replacement agents for DOAC-related bleeding. Our analysis suggests that appropriate utilization of andexanet for reversal of FXa inhibitors in the setting of major gastrointestinal bleeding may result in net reductions in hospitalization costs from a US acute care hospital perspective.
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Surgery: Annexa-S: Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery (clinicaltrials.gov) - Mar 7, 2022
P2, N=10, Terminated, Sponsor: Alexion Pharmaceuticals
Our analysis suggests that appropriate utilization of andexanet for reversal of FXa inhibitors in the setting of major gastrointestinal bleeding may result in net reductions in hospitalization costs from a US acute care hospital perspective. N=100 --> 10 | Trial completion date: Oct 2022 --> Jan 2022 | Recruiting --> Terminated | Trial primary completion date: Sep 2022 --> Nov 2021; Limited value as a single-arm study
- ||| AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Clinical: So Andexanet IS in the market for clinical use? Could you give us a quick perspective on its use? After having a reversal agent for Dabi and use it only once in my career I have stopped following this topic... Thanks a lot! (Twitter) - Mar 7, 2022
- ||| AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca, Ciraparantag (aripazine) / Norgine, Covis Pharma, enoxaparin sodium / Generic mfg.
FDA event: Andexanet alfa has been tested and approved. Also effective for enoxaparin reversal (nobody asked enoxa a reversal agent then but here you have...). Approved by FDA, don't know availability. Other reversals tested: aripazine, cirapanatag. (Twitter) - Mar 7, 2022
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Intracerebral Hemorrhage Severity Predicts Long-Term Functional Outcomes After Anticoagulation Reversal with Andexanet alfa (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2599;
This study implicates targeted reversal with AA in patients presenting with lower ICH scores have more favorable long-term functional outcomes. Additional studies are needed comparing AA to alternative anticoagulation reversal strategies.
- || Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Review, Journal: Review of Target-Specific Anticoagulation Reversal Agents. (Pubmed Central) - Mar 4, 2022
In addition, for agents that continue to lack a targeted reversal agent (eg, low-molecular-weight heparin, antiplatelets, and new antithrombotics), it is imperative that research continues to evaluate improved reversal strategies. This review focuses on target-specific anticoagulation reversal agents currently available in the United States (protamine, idarucizumab, and andexanet alfa) and summarizes agents that are in the pipeline for these anticoagulants and antiplatelets.
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Journal: Case Report: Extended Duration Andexanet Alfa Infusion in a Surgical Trauma Patient. (Pubmed Central) - Mar 3, 2022
Modifications to the andexanet infusion may be required in surgical patients requiring rivaroxaban reversal for a prolonged procedure. Further data are needed to determine the optimal approach to infusion modification.
- ||| AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Andexanet Alfa vs Four-Factor PCC: IS Andexanet Alfa Worth the Hype? via @alyalyoxenfree_ https://t.co/3HPFC6QCCu #FOAMed (Twitter) - Feb 28, 2022
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Andexxa: Clinical Conversation Mechanism of Action (Learning Studio 1, Hall C, Booth 147) - Feb 22, 2022 - Abstract #ISC2022ISC_1791;
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
LS.08 - Andexxa: Clinical Conversation Mechanism of Action (Learning Studio 1, Hall C, Booth 147) - Feb 22, 2022 - Abstract #ISC2022ISC_1790;
- || AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Clinical, Clinical data, Journal, Real-world evidence: Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care. (Pubmed Central) - Feb 19, 2022
P=N/A, P3
As compared with usual care, andexanet alfa was associated with a lower rate of HE in atraumatic factor-Xa inhibitor-related ICH, however, without translating into significantly improved clinical outcomes. A comparative trial is needed to confirm the benefit on limiting HE and to explore clinical outcomes across patient subgroups and by time to treatment.
- Savaysa (edoxaban) / Daiichi Sankyo, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca, Bevyxxa (betrixaban) / AstraZeneca
Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as measured by Whole Blood Thromboelastographic Analysis (hall 1; hall 2; hall 3; hall 4; hall 5) - Feb 16, 2022 - Abstract #GTH2022GTH_283;
Edoxaban exhibited the strongest anticoagulant effect followed by Betrixaban and Rivaroxaban whereas Apixaban showed much weaker anticoagulant effects. AA FC=100 ug/mL showed much stronger, consistent, and complete neutralization effects of all of the 4 FXa Inhibitors when compared to AA at FC=50 ug/mL.
- AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa (hall 1; hall 2; hall 3; hall 4; hall 5) - Feb 16, 2022 - Abstract #GTH2022GTH_173;
In ACT, there appears to be stronger neutralization of UFH at the concentrations tested. Study of the andexanet alfa and anticoagulant interaction in other assays may further clarify the mechanism and/or behavior of neutralization.
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca, Bevyxxa (betrixaban) / AstraZeneca
Journal: 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. (Pubmed Central) - Feb 11, 2022
The information in this manuscript supplements our previous ICSH DOAC laboratory guidance document. The recommendations provided are based on (1) information from peer-reviewed publications about laboratory measurement of DOACs, (2) contributing author's personal experience/expert opinion and (3) good laboratory practice.
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Retrospective data, Journal: Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding. (Pubmed Central) - Feb 3, 2022
A high, but a similar rate of thromboembolic events was seen with both treatments. Prospective studies are needed to elucidate comparative risks and benefits of the 2 agents.
- || AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Retrospective data, Review, Journal: Efficacy and Safety of Andexanet Alfa for Bleeding Caused by Factor Xa Inhibitors: A Systematic Review and Meta-Analysis. (Pubmed Central) - Feb 2, 2022
In conclusion, andexanet alfa reduced in-hospital mortality in patients who had bleeding due to factor Xa inhibitors compared to 4F-PCC. However, there were no differences in thrombotic events, length of ICU, and hospital stay between patients treated with AA and 4F-PCC.
- || AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Trial completion date, Trial primary completion date: Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor (clinicaltrials.gov) - Jan 26, 2022
P4, N=1200, Recruiting, Sponsor: Alexion Pharmaceuticals
However, there were no differences in thrombotic events, length of ICU, and hospital stay between patients treated with AA and 4F-PCC. Trial completion date: Nov 2023 --> Jul 2024 | Trial primary completion date: Mar 2023 --> May 2024
- |||| Savaysa (edoxaban) / Daiichi Sankyo, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Clinical: Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with #Edoxaban: #PHRI’s #ANNEXA4 trial @AlexanderPBenz @johneikelboom Stuart Connolly et al https://t.co/znTNu8L2M6 @TH_Journal (Twitter) - Jan 12, 2022